CRMA-1001
Chronic Hepatitis B Virus (HBV)
Phase 1/2Active
Key Facts
About nChroma Bio
nChroma Bio is a private, preclinical-stage biotech founded in 2020 and headquartered in Boston, MA, USA. The company is pioneering a disease-first approach to genetic medicine, integrating epigenetic and gene-editing cargoes with a modular delivery platform (LNPs for liver, eVLPs for extrahepatic tissues) to create durable, targeted therapies. Its pipeline includes a Phase 1/2 candidate for chronic HBV and earlier research programs in cardiometabolic and CNS diseases, positioning it to address significant unmet needs in both hepatic and non-liver indications.
View full company profile